logo
The record-breaking week in the stock market that could have gone very badly

The record-breaking week in the stock market that could have gone very badly

CNBC11 hours ago

It was another exciting week on Wall Street as the S & P 500 and Nasdaq each closed Friday at new record highs. Incredible as that was, this week could have easily gone another way. Last Saturday, the world learned that the U.S. had entered the Israel-Iran conflict, dropping several massive bunker busters on Fordo, Iran's underground nuclear facility buried under a mountain, and bombing two other sites, Isfahan and Natanz. While fear of further escalation and a prolonged war involving the U.S. was palpable last weekend, the market on Monday shrugged, betting on the notion that the conflict would not result in systemic risk or slow the U.S. economy and hamper corporate earnings much, if at all. As risky as any military action is given the potential to spiral out of control, they tend not to impact the market for long, unless signs appear that it will start impacting growth and inflation. That has not yet happened. We did see energy prices surge in the week before last Saturday's bombings, but they quickly came back down. West Texas Intermediate crude plunged on Monday and Tuesday. While rising modestly in each subsequent session, WTI plunged more than 11% for the week, breaking a three-week winning streak. The stock market took its cues from oil trading, which allowed for the S & P 500 and Nasdaq records and weekly gains of nearly 3.5% and more than 4%, respectively. Monday is the last day of June and Wall Street's second quarter. For the week ... S & P 500 week to date (WTD) up 3.44%; first positive week in three Month to date (MTD) up 4.42%; on pace for its second positive month in a row Quarter to date (QTD) up 10%; on pace for its best quarter since first quarter 2024 Nasdaq WTD up 4.25% MTD up 6%; on pace for its third positive month in a row QTD up 17.2%; best quarter since second quarter 2020 Energy represents a major input cost, often one of the largest, for just about every business in the world, so a sustained increase in energy prices would crunch profit margins or force price hikes in order to preserve them. At the same time, it represents a large unavoidable cost for consumers, whether they're trying to air condition their homes in the summer, heat their homes in the winter, or fill up their cars. Given these high priority needs, elevated energy costs end up cutting into discretionary budgets – meaning activities such as eating out or shopping would get cut back. The quick pairing back of those energy price increases this past week, however, means that analysts don't need to downwardly revise estimates for growth, inflation, or consumer spending – at least not yet. The full impact of President Donald Trump 's tariffs is still unclear, though they will almost certainly lead to higher prices for consumers. While the de-escalation of tensions in the Mideast, and subsequent pullback in energy prices, were certainly the most important factors supporting this week's market action, interest rate expectations were also in focus. Though several voting members of the Federal Reserve's policymaking committee, including Fed Chairman Jerome Powell , threw cold water on comments from Fed Governors Christopher Waller and Michelle Bowman that they were on board with a July rate cut, investors have nonetheless started to price in a higher likelihood that we see three Fed rate cuts by year-end, up from the odds of just two cuts only a week ago. That's according to the CME FedWatch Tool . Another important update that could influence interest rate decisions came Friday, with the release of the May personal income and spending report. Within that report, we find the personal consumption expenditures (PCE) price index, the Fed's preferred measure of inflation. While headline PCE was in line with expectations, up 0.1% month over month and up 2.3% annually, the core rate was a bit hotter than expected, rising 0.2% month over month and 2.7% versus the year-ago period, both one-tenth of a percentage point above expectations. The warmer core reading, which excludes food and energy, is something to watch and cuts against the case for a July rate cut. Digging into the portfolio, we hosted our June Monthly Meeting this week, providing a rundown of all 30 holdings. Jim Cramer highlighted six rallying stocks that members may want to consider booking profits in, and five others that look like buys. We also answered key member questions and touched on all 10 names in our Bullpen, including Cisco Systems, which was added on Monday . The Bullpen is our watch list of stocks that could, under the right circumstances, join the Charitable Trust. During the June meeting, Jim was itching to buy Cisco and Boeing but decided to wait. Sticking with portfolio updates, Nvidia hit new all-time highs this past week as sentiment around artificial intelligence and data center demand continued to improve. Analysts at Loop Capital slapped a $250-per-share price target on the stock, highlighting the hyperscaler purchase intentions over the next few years, the compute intensity of reasoning models, and increased inference demand resulting from AI agent adoption. Already regaining the title of the most valuable U.S. public company at more than $3.8 trillion, Nvidia at $250 represents roughly 60% upside to Friday $157 close and a market cap of more than $6 trillion. Needless to say, Nvidia was our top performer for the week up more than 9.5%. Data center plays — Eaton, GE Vernova, and Broadcom are also expected to benefit from the AI strong demand. On Tuesday, analysts at Morgan Stanley raised their price target on GE Vernova, while analysts at HSBC upgraded Broadcom to a buy from a hold rating. Broadcom, Eaton , and GE Vernova were our next best stocks for the week. Goldman Sachs rounded out the week's top five as financial stocks got some incrementally positive news this week when the Fed, on Wednesday, proposed lowering capital requirements for large U.S banks that were implemented in the years following the 2008 financial crisis. The move would allow banks, including Club holdings Goldman and Wells Fargo , to lend more freely while making it easier for them to buy more U.S. government bonds. Amazon continues to be in the news as investors work to better understand the opportunity the company has in new areas like online grocery shopping, thanks to its massive logistics network and the implications of advancing it through generative AI, robotics and autonomous vehicles. In health care, shares of Eli Lilly advanced this week despite data released Monday on the company's experimental weight-loss drug, bimagrumab, which is designed to help patients preserve muscle mass. It failed to wow investors. Abbott Laboratories , meanwhile, got some positive news Tuesday when Health & Human Services Secretary Robert F. Kennedy Jr. said that his department will encourage the use of wearable health devices. "My vision is every American is wearing a wearable within four years," RFK Jr. said at a House Energy and Commerce Committee meeting . The news may also bode well for devices like the Apple Watch, especially as more health-related sensors are built in. Speaking of Apple , we still believe it is an incredible company with the "greatest product in the world," as Jim put it , referring to the iPhone. However, we think the company would benefit from modifying its capital allocation plans , focusing less on the buyback and more on AI development, be it via internal R & D, paying up for top talent, or acquiring groundbreaking startups. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What Texas Instruments Capital Strength Means for Its Dividend
What Texas Instruments Capital Strength Means for Its Dividend

Yahoo

time18 minutes ago

  • Yahoo

What Texas Instruments Capital Strength Means for Its Dividend

Texas Instruments Incorporated (NASDAQ:TXN) is one of the Best Stocks to Buy for Dividends. A robotic arm in the process of assembling a complex circuit board - showing the industrial scale the company operates at. The company follows a strong business model centered on analog and embedded processing products, supported by its long-lasting competitive strengths. Another key part of its strategy to drive long-term growth in free cash flow per share is its disciplined approach to capital allocation. This includes careful selection of research and development projects, building new capabilities, investing in manufacturing capacity, evaluating potential acquisitions, and returning capital to shareholders. Texas Instruments Incorporated (NASDAQ:TXN)'s strategy also focuses on efficiency, which it defines as consistently aiming to generate greater results for every dollar spent. This approach emphasizes directing investments toward the most impactful areas to support the long-term growth of free cash flow per share, rather than simply cutting costs to the bare minimum. For shareholders, this commitment to efficiency is expected to support revenue growth, stronger gross margins, careful management of R&D and SG&A expenses, healthy free cash flow margins, and ultimately, an increase in free cash flow per share. Texas Instruments Incorporated (NASDAQ:TXN) currently offers a quarterly dividend of $1.36 per share. Overall, the company has raised its payouts for 21 consecutive years. In the past five years, it has raised its payouts at an annual average rate of over 9%, which is considered a solid pace in the tech sector. As of June 25, TXN has a dividend yield of 2.65%. While we acknowledge the potential of TXN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Yahoo

time38 minutes ago

  • Yahoo

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ardelyx (ARDX) Appoints New Chief Business and HR Officers
Ardelyx (ARDX) Appoints New Chief Business and HR Officers

Yahoo

time38 minutes ago

  • Yahoo

Ardelyx (ARDX) Appoints New Chief Business and HR Officers

Ardelyx, Inc. (NASDAQ:ARDX) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company announced two key appointments to its leadership team. Mike Kelliher, who joined the company in March 2024, was promoted from his previous role as Executive Vice President, Corporate Development and Strategy to Chief Business Officer (CBO). James P. Brady joined Ardelyx as the new Chief Human Resources Officer (CHRO). Both Kelliher and Brady report directly to Mike Raab, the company's President and CEO. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. Ardelyx said that these appointments are part of its strategy to strengthen its leadership team. The move, the company stated, is crucial to advancing its commercial and clinical programs. 'As we continue to grow and evolve our business, it is imperative that we have high caliber leaders, like Mike and Jamie, who will enable us to accelerate our momentum and deliver long-term impact for patients and shareholders,' said Raab. The CEO highlighted Kelliher's experiences, business intuition, and leadership as bringing 'incredible value' to Ardelyx. On the other hand, he expressed excitement about welcoming Brady, emphasizing his talent as an HR executive and his extensive experience in people development, which will be influential in advancing key business initiatives and talent strategies. Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company. It discovers, develops, and commercializes first-in-class medicines for gastrointestinal and kidney diseases. Its key products include IBSRELA (for irritable bowel syndrome with constipation) and XPHOZAH (a phosphate absorption inhibitor for chronic kidney disease patients on dialysis). Ardelyx serves adult patients in the United States and internationally. While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store